InvestorsHub Logo
Followers 37
Posts 7291
Boards Moderated 1
Alias Born 09/06/2014

Re: guardiangel post# 25492

Saturday, 10/04/2014 11:03:26 AM

Saturday, October 04, 2014 11:03:26 AM

Post# of 30046
That is not what I claim.

I claim that LC Sentinel was Provista's re-packaging of the DR-70 reagents that detect fibrin and fibrinogen. LC Sentinel used Radient's reagents, not a combination of Radient's reagents and some magic beans that Provista had laying around.

http://www.proactiveinvestors.com/companies/news/9163/radient-pharmaceuticals-and-provista-announce-introduction-of-new-diagnostic-lung-cancer-test-9163.html

"The study completed the requisite analyses needed to validate Provista's test, based on Radient's antigens for fibrinogen degradation products (FDP), which successfully detect lung cancer with a high degree of accuracy, according to the companies."

"The study included men and women between 20-76 years of age and showed consistent findings with previous tests, producing positive clinical performance marks of 87% sensitivity, 95% specificity, and an ROC Accuracy of 0.97.

According to Provista, the study will now serve as the cornerstone of its efforts to introduce a new lung cancer detection test called LC Sentinel to the market."

That's DR-70, wolfie. Nothing else.

But just for fun, let's pretend that LC Sentinel was a combination of DR-70 and some Provista magic beans as you claim. DR-70 is off patent now. That STILL does not involve Radient. Gartner might be paying Provista some royalties or licensing fees for the magic beans but he is not paying Radient anything for DR-70. First of all, Radient does not exist at the moment. Second, DR-70 is off patent so Gartner can use it for free even if Radient did exist.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.